QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity
Frederick, MD – January 24, 2023 Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio. (more…)
PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT
Proven Life Sciences Leader Takes Reins to Continue Rapid Growth and
Drive Next-Gen Commercialization Model
BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.
New Tech on the Rise: The Future of Cell and Gene Therapies Is Here
Recent headlines suggest that the biotech industry as a whole is experiencing a downturn, yet in spite of this narrative the momentum for advanced therapies continues to persevere. Many companies in the cell and gene therapy space are dedicated to bringing these novel therapies to the patients who need them. In this article for PM360 Magazine, Precision’s Anshul Mangal explores the breakthroughs taking place in autologous cell therapies, non-viral delivery methods, and gene editing technologies that may improve patient access for life-saving treatments.
On-Demand: The Hitchhiker’s Guide to CGTx in 2023
Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.
Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).
Article: Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts
Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.
- Assessing commercial viability
- Developing clinical trial design and evidence-generation strategy
- Planning for launch preparedness
Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.